These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33743997)

  • 41. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of completion thyroidectomy followed by radioactive iodine ablation for patients with lymph node recurrence of papillary thyroid carcinoma.
    Saito Y; Matsuzu K; Sugino K; Takami H; Kitagawa W; Nagahama M; Ito K
    Surgery; 2019 Sep; 166(3):342-348. PubMed ID: 31128851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States.
    Sawka AM; Rotstein L; Brierley JD; Tsang RW; Thabane L; Gafni A; Straus S; Kamalanathan S; Zhao B; Goldstein DP; Rambaldini G; Ezzat S
    Thyroid; 2007 Dec; 17(12):1235-42. PubMed ID: 17988197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
    Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence.
    Hay ID; Johnson TR; Thompson GB; Sebo TJ; Reinalda MS
    Surgery; 2016 Jan; 159(1):11-9. PubMed ID: 26514317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
    Dietlein M; Luyken WA; Schicha H; Larena-Avellaneda A
    Nucl Med Commun; 2005 Jan; 26(1):3-8. PubMed ID: 15604941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment.
    Abelleira E; Peñaloza MA; Jerkovich F; Bueno F; Pitoia F
    Arch Endocrinol Metab; 2021 Nov; 65(3):315-321. PubMed ID: 34731559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine.
    Mujammami M; Hier MP; Payne RJ; Rochon L; Tamilia M
    Thyroid; 2016 Jul; 26(7):951-8. PubMed ID: 27150203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
    Patel SS; Goldfarb M
    J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis.
    Muller S; Senne M; Kirschniak A; Königsrainer A; Bares R; Falch C
    World J Surg Oncol; 2017 Oct; 15(1):190. PubMed ID: 29065879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How Important is the Timing of Radioiodine Ablation in Differentiated Thyroidal Carcinomas: A Referral Centre Experience.
    Simsek FS; Balci TA; Donder Y; Ugur K; Kilinc F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(3):157-162. PubMed ID: 31982352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-risk papillary thyroid cancer recurrence in patients treated with total thyroidectomy and adjuvant therapy vs. patients treated with partial thyroidectomy.
    Hurtado-López LM; Melchor-Ruan J; Basurto-Kuba E; Montes de Oca-Durán ER; Pulido-Cejudo A; Athié-Gutiérrez C
    Cir Cir; 2011; 79(2):118-25. PubMed ID: 21631972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.
    Castagna MG; Cantara S; Pacini F
    J Endocrinol Invest; 2016 Oct; 39(10):1087-94. PubMed ID: 27350556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer.
    Tian T; Jiang L; Zhang X; Huang R; Liu B
    Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis.
    Yang T; Zheng SY; Jiao J; Zou Q; Zhang Y
    Nucl Med Commun; 2019 Jul; 40(7):711-719. PubMed ID: 31095043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of patients with low-risk papillary thyroid carcinoma.
    Hay ID
    Endocr Pract; 2007 Sep; 13(5):521-33. PubMed ID: 17872355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.